Lilly Plans to Invest Additional $450 million at Manufacturing Site in Research Triangle Park | Eli Lilly and Company

INDIANAPOLIS,
Jan. 28, 2022
/PRNewswire/ — Eli Lilly and Company (NYSE: LLY) plans to invest over
$1 billion
to create a new manufacturing site, forth with nearly 600 new jobs in
Concord, Northward Carolina. The make-new facility will utilize the latest applied science to industry parenteral (injectable) products and devices and increase the visitor’s manufacturing capacity.

“Lilly is entering an heady period of growth and we are committed to delivering innovative medicines to patients around the world,” said Edgardo Hernandez, senior vice president and president, Lilly Manufacturing Operations. “Expanding our manufacturing footprint in
North Carolina
enables united states to proceed to produce today’due south medicines while providing additional capacity to manufacture the medicines of tomorrow. We are pleased to again partner with
North Carolina
to bring jobs to American workers and provide more medicines that patients demand to address wellness challenges.”

Lilly selected
Concord
because of the manufacturing applied science experience of the local labor force; its proximity to universities with potent science, technology, engineering and math (STEM) programs; and its admission to major transportation infrastructure. In 2020, Lilly announced a
$470 million
investment in
Northward Carolina’southward
Inquiry Triangle Park. In conjunction with this site, the new facility in
Hold
will allow the company to strengthen relationships with local governments and universities and diversify its growing presence in the land.

Lilly plans to create nearly 600 new jobs for highly skilled workers such every bit scientists, engineers and manufacturing personnel, who volition employ advanced technology to produce life-changing treatments and devices to make life improve for people around the world. In addition, an estimated 500 boosted positions will be required while the facility is nether construction.

“Lilly’s choice brings more good jobs to
North Carolina
from one of our most important industries,” said
North Carolina
Governor
Roy Cooper. “North Carolina
has become a premier hub for the world, thanks to our exceptional workforce and commitment to education.”

Over the last 5 years, Lilly has invested over
$4 billion
in global manufacturing, including more than
$2 billion
in the U.S. The company likewise today appear plans to invest
$500 million
in a new biopharmaceutical manufacturing facility in Limerick, Republic of ireland. Lilly anticipates additional future investments in manufacturing to address growth expected from potential new medicines to care for diabetes, Alzheimer’south affliction, cancer and autoimmune weather condition.

The investment in
Concord
is contingent upon completion of county and municipal regime permitting and related approvals. Lilly partnered with several organizations throughout the projection, including the Office of the Governor, the Department of Commerce, Cabarrus Economical Development Corporation, the
City of Concord,
Cabarrus Canton, the Economic Development Partnership of
North Carolina, the N Carolina Biotechnology Centre, Rowan Cabarrus Customs College, and the North Carolina Community College Organisation.

Near Eli Lilly and Company



Lilly is a global health care leader that unites caring with discovery to create medicines that make life ameliorate for people around the globe. We were founded more than a century ago past a man committed to creating high-quality medicines that meet existent needs, and today we remain true to that mission in all our work. Across the world, Lilly employees work to discover and bring life-changing medicines to those who demand them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit united states of america at lilly.com and lilly.com/newsroom. C-LLY

This press release contains forward-looking statements (as that term is defined in the Individual Securities Litigation Reform Act of 1995) about planned capital investments in a new manufacturing site and reflects Lilly’southward current conventionalities.  There are substantial risks and uncertainties in the manufacturing procedure, development, and commercialization of pharmaceutical products which could impact the overall commercial success of our products. For further discussion of these and other risks and uncertainties, see Lilly’s near recent Form 10-K and Course 10-Q filings with the The states Securities and Exchange Committee. Except equally required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the appointment of this release.

SOURCE Eli Lilly and Company